Source-grounded facts extracted from Hims & Hers Health, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Hims & Hers Health, Inc. shareholders approved Advisory approval of the Company’s executive compensation at the 2026-06-11 meeting.
“Proposal 3 : Advisory approval of the Company’s executive compensation: For Against Abstentions Broker Non-Votes 1,506,477,171 11,181,420 309,881 74,228,233”
Hims & Hers Health, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
“Proposal 2 : The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: For Against Abstentions 1,591,246,881 516,386 433,438 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.”
Hims & Hers Health, Inc. shareholders approved Election of nine directors to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified at the 2026-06-11 meeting.
“Proposal 1 : The election of nine directors to serve as directors until the 2027 annual meeting of stockholders and until their respective successors are duly elected and qualified: Name For Withheld Broker Non-Votes Andrew Dudum 1,504,939,830 13,028,642 74,228,233 Kofi Amoo-Gottfried 1,517,440,666 527,806 74,228,233 Deborah Autor 1,516,370,269 1,598,203 74,228,233 Delos Cosgrove, M.D. 1,516,949,085 1,019,387 74,228,233 Anja Manuel 1,516,973,593 994,879 74,228,233 Christopher Payne 1,508,808,309 9,160,163 74,228,233 Andrea Perez 1,516,871,986 1,096,486 74,228,233 Kare Schultz 1,516,971,244 997,228 74,228,233 David Wells 1,501,758,393 16,210,079 74,228,233”
Hims & Hers Health, Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent, and the lenders and issuing banks party thereto (effective 2026-05-29).
“On May 29, 2026, Hims & Hers Health, Inc. (the “ Company ”), as borrower, entered into Amendment No. 3 (the “ Amendment ”) to the Revolving Credit and Guaranty Agreement, dated as of February 18, 2025 (as amended by that certain Amendment No. 1 to the Revolving Credit and Guaranty Agreement, dated as of June 25, 2025, that certain Amendment No. 2 to the Revolving Credit and Guaranty Agreement, dated as of May 7, 2026, and as amended by this Amendment, the “ Credit Agreement ”), by among the Company, the subsidiary borrowers and the guarantors from time to time party thereto, the lenders and issuing banks party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.”
Hims & Hers Health, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $402.5 million aggregate principal amount (effective 2026-05-21).
“the Notes were issued pursuant to, and are governed by, an indenture (the “ Indenture ”), dated as of May 21, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee”
Hims & Hers Health, Inc. incurred convertible notes of $402.5 million with U.S. Bank Trust Company, National Association at 0.00% maturing June 1, 2032.
“On May 21, 2026, the Company issued $402.5 million aggregate principal amount of Notes.”
Hims & Hers Health, Inc. reported the first quarter ended March 31, 2026 results: revenue $608.1 million, net income $92.1 million. Guidance raised.
“Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results Revenue of approximately $608 million, up 4% year-over-year in Q1 2026”
Hims & Hers Health, Inc. entered into Securities Sale Deed with the sellers party thereto valued at up to approximately $1,150,000,000 (effective 2026-02-19).
“On February 19, 2026, Hims & Hers Health, Inc. (the “ Company ”), Hims, Inc. (the “ Guarantor ”), and Horizon BidCo Pty Ltd ACN 694 778 375, an Australian proprietary company (the “ Purchaser ”) and wholly-owned subsidiary of the Company, entered into a Securities Sale Deed (the “ Deed ”) with the sellers party thereto (the “ Sellers ”), pursuant to which, among other things, the Sellers agreed to sell and Purchaser agreed to purchase from each Seller (the “ Proposed Acquisition ”) all of the issued capital (the “ Target Equity ”) of EUC Management Pty Ltd ACN 631 013 860 (d/b/a Eucalyptus) (the “ Target ”).”
Hims & Hers Health, Inc. incurred convertible notes of $1.0 billion aggregate principal amount of Notes with U.S. Bank Trust Company, National Association at 0.00% maturing May 15, 2030.
“On May 13, 2025, the Company issued $1.0 billion aggregate principal amount of Notes.”
Melissa Baird changed role as Chief Operating Officer at Hims & Hers Health, Inc..
“Melissa Baird, Chief Operating Officer of Hims & Hers Health, Inc. (the “Company”), announced her intention to transition into an advisory role with Hims & Hers in the coming months.”
Deb Autor was appointed as Director at Hims & Hers Health, Inc..
“On November 15, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Deb Autor, 57, to fill the newly created vacancy, effective immediately.”
Hims & Hers Health, Inc. reported the first quarter ended March 31, 2024 results: revenue Revenue of $278.2 million, net income Net income of $11.1 million. Guidance raised.
“be expressly set forth by specific reference in such a filing. --- EX-99.1 (EX-99.1) --- Hims & Hers Health, Inc. Reports First Quarter 2024 Financial Results Revenue of $278.2 million, up 46% year-over-year in 2024 Net income of $11.1 million; Adjusted EBITDA of $32.3 million in Q1 2024 Subscribers grew to 1.7 million, up 41% year-over-year in Q1 2024 Raises”
Anja Manuel was appointed as Director at Hims & Hers Health, Inc..
“On April 24, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from ten to eleven directors and appointed Anja Manuel, 49, to fill the newly created vacancy, effective immediately.”
Christopher Payne was appointed as Director at Hims & Hers Health, Inc..
“On March 30, 2024, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) increased the size of the Board from nine to ten directors and appointed Christopher Payne, 55, to fill the newly created vacancy, effective March 30, 2024.”
Hims & Hers Health, Inc. reported the year ended December 31, 2023 results: revenue $872.0 million, net income $(23.5) million. Guidance initiated.
“Revenue was $872.0 million for the year ended December 31, 2023 compared to $526.9 million for the year ended December 31, 2022, an increase of 65% year-over-year. • Gross margin was 82% for the year ended December 31, 2023 compared to 78% for the year ended December 31, 2022. • Net loss was $(23.5) million for the year ended December 31, 2023 compared to $(65.7) million for the year ended December 31, 2022.”
Hims & Hers Health, Inc. reported the fourth quarter of 2023 results: revenue $246.6 million, net income $1.2 million. Guidance initiated.
“Revenue was $246.6 million for the fourth quarter of 2023 compared to $167.2 million for the fourth quarter of 2022, an increase of 47% year-over-year. • Gross margin was 83% for the fourth quarter of 2023 compared to 79% for the fourth quarter of 2022. • Net income was $1.2 million for the fourth quarter of 2023 compared to a net loss of $(10.9) million for the fourth quarter of 2022.”
Hims & Hers Health, Inc. reported the quarter ended September 30, 2023 results: revenue $226.7 million, net income $(7.6) million. Guidance raised.
“Hims & Hers Health, Inc. Reports Third Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $226.7 million, up 57% year-over-year in Q3 2023 Net loss of $7.6 million”
Hims & Hers Health, Inc. reported the quarter ended June 30, 2023 results: revenue $207.9 million, net income $(7.2) million. Guidance raised.
“reference in such a filing. --- EX-99.1 (EX-99.1) --- Hims & Hers Health, Inc. Reports Second Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $207.9 million, up 83% year-over-year in Q2 2023 Net loss of $7.2 million; Adjusted EBITDA profitability of $10.6 million in Q2 2023 Subscribers grew to 1.3 million, up 74% year-over-year in Q2”
Hims & Hers Health, Inc. shareholders approved Advisory approval of the Company’s executive compensation at the 2023-06-01 meeting.
“Proposal 3 : Advisory approval of the Company’s executive compensation: For Against Abstentions Broker Non-Votes 1,529,000,617 16,445,485 436,802 27,820,587”
Hims & Hers Health, Inc. shareholders approved Ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-01 meeting.
“Proposal 2 : The ratification of the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstentions 1,572,576,823 784,991 341,677 As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.”
Hims & Hers Health, Inc. shareholders approved Election of nine directors to serve until the 2024 annual meeting of stockholders and until their respective successors are duly elected and qualified at the 2023-06-01 meeting.
“Proposal 1 : The election of nine directors to serve as directors until the 2024 annual meeting of stockholders and until their respective successors are duly elected and qualified: Name For Withheld Broker Non-Votes Andrew Dudum 1,518,932,917 26,949,987 27,820,587 Alex Bard 1,509,800,643 36,082,261 27,820,587 Ambar Bhattacharyya 1,518,850,823 27,032,081 27,820,587 Dr. Patrick Carroll, M.D. 1,518,847,280 27,035,624 27,820,587 Dr. Delos Cosgrove, M.D. 1,510,988,374 34,894,530 27,820,587 Lynne Chou O’Keefe 1,510,789,427 35,093,477 27,820,587 Christiane Pendarvis 1,545,352,089 530,815 27,820,587 Andrea Perez 1,519,018,363 26,864,541 27,820,587 David Wells 1,506,466,035 39,416,869 27,820,587”
Hims & Hers Health, Inc. reported the first quarter ended March 31, 2023 results: revenue $190.8 million, net income $(10.1) million. Guidance raised.
“Hims & Hers Health, Inc. Reports First Quarter 2023 Financial Results and Raises Full Year 2023 Outlook Revenue of $190.8 million, up 88% year-over-year in Q1 2023 Net loss of $10.1 million; Adjusted EBITDA profitability of $6.1 million in Q1 2023 Subscribers grew to over 1.2 million, up 87% year-over-year in Q1 2023 Raises full year 2023 revenue guidance to a range of $810 million to $830 million and Adjusted EBITDA guidance to a range of $25 million to $30 million”
Hims & Hers Health, Inc. reported Full Year 2023 results: revenue $735 million to $755 million. Guidance initiated.
“Provides Q1 and full year 2023 guidance, with full year 2023 revenue in the range of $735 million to $755 million and Adjusted EBITDA in the range of $20 million to $30 million”
Hims & Hers Health, Inc. reported Full Year 2022 results: net income $(65.7) million.
“Full year 2022 revenue of $526.9 million, up 94% year-over-year”
Hims & Hers Health, Inc. reported Q4 2022 results: revenue $167.2 million, net income $(10.9) million.
“Q4 2022 record revenue of $167.2 million, up 97% year-over-year Q4 2022 net loss of $10.9 million and achieves Adjusted EBITDA profitability of $3.9 million”
Christiane Pendarvis was appointed as director at Hims & Hers Health, Inc..
“appointed Christiane Pendarvis, 52, to fill the newly created vacancy, effective February 16, 2023.”
Hims & Hers Health, Inc. reported third quarter ended September 30, 2022 results: revenue Revenue was $144.8 million for the third quarter 2022 compared to $74.2 million for the third quarter 2021, net income Net loss was $(18.8) million for the third quarter 2022 compared to $(15.9) million for the third quarter 2021. Guidance raised.
“Hims & Hers Health, Inc. Reports Third Quarter 2022 Financial Results and Raises Full Year 2022 Outlook; Platform Demand and Financial Outperformance Driving Expected Adjusted EBITDA Profitability Beginning in Q4 2022 Quarterly revenue of $144.8 million in Q3 2022”
Irene Becklund changed role as Interim Chief Financial Officer at Hims & Hers Health, Inc..
“Irene Becklund, the Company’s controller, who is serving as interim principal financial officer and principal accounting officer as disclosed in the Company’s Current Report on Form 8-K filed on November 18, 2021, will continue as the Company’s principal accounting officer but will cease serving as interim principal financial officer upon the effectiveness of Mr. Okupe’s appointment.”
Patrick Carroll was appointed as Director at Hims & Hers Health, Inc..
“appointed Dr. Patrick Carroll, M.D., 63”
Patrick Carroll resigned as Chief Medical Officer at Hims & Hers Health, Inc..
“Resignation of Chief Medical Officer”
Oluyemi Okupe was appointed as Chief Financial Officer and Principal Financial Officer at Hims & Hers Health, Inc..
“On January 18, 2022, the board of directors (the “Board”) of Hims & Hers Health, Inc. (the “Company”) appointed Oluyemi Okupe as chief financial officer and principal financial officer of the Company, effective January 24, 2022.”
Irene A. Becklund was appointed as Interim Principal Financial Officer and Principal Accounting Officer at Hims & Hers Health, Inc..
“the Company’s board of directors appointed Irene A. Becklund as interim principal financial officer and principal accounting officer of the Company, effective immediately.”
Spencer Lee resigned as Chief Financial Officer at Hims & Hers Health, Inc..
“On November 15, 2021, Spencer Lee resigned from his position as chief financial officer, principal financial officer and principal accounting officer of Hims & Hers Health, Inc. (the “Company”) consistent with previously disclosed plans for Mr. Lee to transition out of the Company.”
Spencer Lee resigned as Chief Financial Officer at Hims & Hers Health, Inc..
“On August 31, 2021, Spencer Lee informed Hims & Hers Health, Inc. (the “Company”) of his intention to resign as Chief Financial Officer (“CFO”) and Treasurer.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.